Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
US-9139821-B2 · Sep 22, 2015 · US
US9708588B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9708588-B2 |
| Application number | US-201615180355-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 13, 2016 |
| Priority date | Mar 23, 2012 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.
Opening claim text (preview).
What is claimed is: 1. An engineered polynucleotide encoding a polypeptide having transaminase activity, wherein said polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 4 and one or more residue differences as compared to SEQ ID NO:4, wherein said polypeptide comprises a substitution at residue position X163L. 2. The engineered polynucleotide of claim 1 , in which the residue differences in said encoded polypeptide having transaminase activity further comprises substitutions at the residue positions X14; X26; X33; X41; X47; X70; X88; X107; X132; X148; X173; X203; X250; X284; X315; X346; X395; X400; X419; X423; X448; and X451, wherein said substitutions are selected from X14V; X26R; X33T; X41L; X47N; X70A; X88A; X88L; X107P; X132F; X148Q; X148R; X173A; X203S; X250A; X284A; X315G; X346L; X395P; X400G; X419S; X423I; X448E; and X451D. 3. The engineered polynucleotide of claim 2 , in which the amino acid sequence of said encoded polypeptide having transaminase activity further comprises one or more residue differences selected from: X57F; X113L; X113V; X168K; X420N; and X424V. 4. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity further comprises at least one or more residue differences selected from: X14V; X26R; X315/D; X86D; X163I/L/R/V; X284A; X315G; X398L/V/W; and X400G. 5. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity further comprises a combination of residue differences selected from: X14V and X163I/L/R/V; X86D and X400G; X57F/Y and X163I/L/R/V; X57F/Y and X398L/V/W; X14V, X113L/V, X163I/L/R/V, X284A, and X424V; X31S, X57F/Y, X163I/L/R/V, X315G, X346L, and X398L/V/W X14V, X113L, X163L, X284A, and X424V; X14V, X26R, X163L, X284A, and X400G; X14V, X26R, X88L, and X113L; X57F, X163L, X168K, X314N, X315G, X346L, and X398V; X14V, X163L, X173A, X400G, and X420N; X14V, X113L, X163L, and X284A; X14V, X26R, X163L, X284A, and X400G; and X14V, X33T, X57F, X113L, and X163L. 6. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity has at least 1.2 fold increased stability as compared to the polypeptide of SEQ ID NO:4, wherein the amino acid sequence further comprises one or more residue differences selected from: X14V; X26R; X31S; X33T; X41L; X70A; X86D; X88A/L; X163I/L/R/V; X284A; X324H; X419S; and X423I. 7. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity comprises SEQ ID NO:6. 8. An expression vector comprising the polynucleotide of claim 1 . 9. The expression vector of claim 8 , further comprising at least one control sequence. 10. The expression vector of claim 9 , wherein said control sequence comprises a promoter. 11. A host cell comprising the polynucleotide of claim 1 . 12. A host cell comprising the expression vector of claim 8 . 13. A host cell comprising the expression vector of claim 9 . 14. A host cell comprising the expression vector of claim 10 . 15. The host cell of claim 11 , wherein said host cell is E. coli. 16. The host cell of claim 12 , wherein said host cell is E. coli. 17. The host cell of claim 13 , wherein said host cell is E. coli. 18. The host cell of claim 14 , wherein said host cell is E. coli. 19. A method of preparing an engineered polypeptide having transaminase activity, comprising culturing the host cell of claim 11 under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide. 20. A method of preparing an engineered polypeptide having transaminase activity, comprising culturing the host cell of claim 12 under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.
Nitrogen as only ring hetero atom · CPC title
transferring nitrogenous groups (2.6) · CPC title
Transaminases (2.6.1) · CPC title
using catalysts, e.g. selective catalysts · CPC title
Beta-alanine-pyruvate transaminase (2.6.1.18) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.